Home / Innere Medizin / Onkologie / Breakfast Brief: An update on lung cancer

Breakfast Brief: An update on lung cancer

In this Breakfast Brief, PD DDr. Sacha Rothschild, Universitätsspital Basel, summarizes his personal highlights of the first two days of ESMO Congress 2018.

Interview Partner(s):

Editor:

Production:

Starting with news regarding trials with ALK-positive Non-Small Cell Lung Cancer: ALTA-1L, showing superior intracranial activity in TKI-naive stage IIIB/IV patients, the ALEX trial with efficacy data by EML4-ALK variant group and ASCEND-8, presenting a more favorable GI safety profile.

Also, an update of FLAURA was presented, that reported preliminary data on mechanisms of acquired resistance to osimertinib in patients with previously untreated EGFRm advanced NSCLC who progressed during the study.

Two MET-Inhibitors, capmatinib and tepotinib demonstrated promising antitumor activity in patients with MET overexpression and gene amplification.

PD DDr. Sacha Rothschild presented parts of the following abstracts in this Breakfast Brief:

#LBA58:  Popat S et al.: Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase 3 ALTA-1L-trial

#1379PD: Dziadziuszko R et al.: Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study

#LBA59: Cho BC et al.: Primary efficacy and updated safety of ceritinib (450mg or 600mg) with food vs 750mg fasted in Alk+ metastatic NSCLC (ASCEND-8)

#LBA50: Ramalingam SS et al.: Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study

#LBA51: Papadimitrakopoulou VA et al.: Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

#LBA52: Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

#13770: Wu Y et al.: Phase 2 study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non small cell lung cancer (NSCLC)

Source: ESMO 2018 Congress

LOGIN

Login

Passwort vergessen?